Related references
Note: Only part of the references are listed.ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
Daniel W. Lee et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2019)
Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia
Nicola Goekbuget et al.
BLOOD (2018)
Delayed High-dose Methotrexate Excretion and Influencing Factors in Osteosarcoma Patients
Wei Zhang et al.
CHINESE MEDICAL JOURNAL (2016)
Phase I/Phase II Study of Blinatumomab in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia
Arend von Stackelberg et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Blinatumomab: a bispecific T cell engager (BiTE) antibody against CD19/CD3 for refractory acute lymphoid leukemia
Jingjing Wu et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2015)
Treatment reduction for children and young adults with low-risk acute lymphoblastic leukaemia defined by minimal residual disease (UKALL 2003): a randomised controlled trial
Ajay Vora et al.
LANCET ONCOLOGY (2013)
SMARCAL1 Deficiency Predisposes to Non-Hodgkin Lymphoma and Hypersensitivity to Genotoxic Agents In Vivo
Alireza Baradaran-Heravi et al.
AMERICAN JOURNAL OF MEDICAL GENETICS PART A (2012)
Bispecific T-Cell Engaging Antibodies for Cancer Therapy
Patrick A. Baeuerle et al.
CANCER RESEARCH (2009)
The annealing helicase SMARCAL1 maintains genome integrity at stalled replication forks
Carol E. Bansbach et al.
GENES & DEVELOPMENT (2009)
Share Paper
